Efficacy of Omalizumab, an Anti-immunoglobulin E Antibody, in Patients with Allergic Asthma at High Risk of Serious Asthma-related Morbidity and Mortality

This publication has 17 references indexed in Scilit:

• Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
  Journal of Allergy and Clinical Immunology, 2001
• Spiral Computed Tomography Screening for Lung Cancer Is Ready for Prime Time
  American Journal of Respiratory and Critical Care Medicine, 2001
• Risk factors and costs associated with an asthma attack
  Thorax, 2000
• IgE Inhibition as a Therapy for Allergic Disease
  International Archives of Allergy and Immunology, 1999
• Difficult asthma
  European Respiratory Journal, 1998
• Inhaled Corticosteroids and the Prevention of Readmission to Hospital for Asthma
  American Journal of Respiratory and Critical Care Medicine, 1998
• Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity.
  Thorax, 1996
• Is the Association between Inhaled Beta-Agonist Use and Life-threatening Asthma because of Confounding by Severity?
  American Review of Respiratory Disease, 1993
• Markers of Risk of Asthma Death or Readmission in the 12 Months Following a Hospital Admission for Asthma
  International Journal of Epidemiology, 1992
• A case-control study of deaths from asthma.
  Thorax, 1986